User menu

A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate

Bibliographic reference Neven, Patrick ; Lunde, Tore ; Benedetti-Panici, Pierluigi ; Tiitinen, Aila ; Marinescu, Bogdan ; et. al. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate. In: BJOG : an international journal of obstetrics and gynaecology, Vol. 110, no. 2, p. 157-167 (2003)
Permanent URL
  1. Barrett-Connor E, BMJ, 317, 457 (1998)
  2. Writing Group for the Women's Health Initiative Investigators, JAMA, 288, 321 (2002)
  3. Legault C, Menopause, 6, 325 (1999)
  4. Collaborative Group on Hormonal Factors in Breast Cancer, Lancet, 350, 1047 (1997)
  5. Love R. R., Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years, 10.1001/archinte.154.22.2585
  6. Ettinger Bruce, Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical Trial, 10.1001/jama.282.7.637
  7. Fisher Bernard, Costantino Joseph P., Wickerham D. Lawrence, Redmond Carol K., Kavanah Maureen, Cronin Walter M., Vogel Victor, Robidoux André, Dimitrov Nikolay, Atkins James, Daly Mary, Wieand Samuel, Tan-Chiu Elizabeth, Ford Leslie, Wolmark Norman, Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, 10.1093/jnci/90.18.1371
  8. Cummings Steven R., Eckert Stephen, Krueger Kathryn A., Grady Deborah, Powles Trevor J., Cauley Jane A., Norton Larry, Nickelsen Thomas, Bjarnason Nina H., Morrow Monica, Lippman Marc E., Black Dennis, Glusman Joan E., Costa Alberto, Jordan V. Craig, The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women : Results From the MORE Randomized Trial, 10.1001/jama.281.23.2189
  9. IBIS investigators, Lancet, 360, 817 (2002)
  10. Neven P, Drug Saf, 22, 1 (2000)
  11. Delmas Pierre D., Bjarnason Nina H., Mitlak Bruce H., Ravoux Anne-Catherine, Shah Aarti S., Huster William J., Draper Michael, Christiansen Claus, Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women, 10.1056/nejm199712043372301
  12. Davies GC, Menopause, 6, 188 (1999)
  13. Cohen F, Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60, 10.1016/s0029-7844(99)00554-2
  14. Goldstein S, A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium, 10.1016/s0029-7844(99)00502-5
  15. Boss S, Am J Obstet Gynecol, 177, 1458 (1997)
  16. Fugere P, Am J Obstet Gynecol, 182, 568 (2000)
  17. 17. EE Jolly, and WH Scheele . A high dose of raloxifeneHCl is not stimulatory in the uterus of healthy postmenopausal women [abstract] . IV European Congress on Menopause Abstract Book, 1997 October 8-12, Vienna, Austria. Paris, FR: Editions ESKA, 1997:68 (Abstract no. FC5-8).
  18. Larkin M, Lancet, 355, 1338 (2000)
  19. Weiderpass E., Adami H.-O., Baron J. A., Magnusson C., Bergstrom R., Lindgren A., Correia N., Persson I., Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins, 10.1093/jnci/91.13.1131
  20. Doren M, Menopause, 6, 299 (1999)
  21. Hulley Stephen, Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women, 10.1001/jama.280.7.605
  22. Herrington David M., Reboussin David M., Brosnihan K. Bridget, Sharp Penny C., Shumaker Sally A., Snyder Thomas E., Furberg Curt D., Kowalchuk Glen J., Stuckey Thomas D., Rogers William J., Givens David H., Waters David, Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis, 10.1056/nejm200008243430801